Skip to main content

Metformin

Source index · review incomplete

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated July 17, 2026; this date does not indicate completed review.

Hormones1,797 cited mentions
Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on Metformin; the papers are listed at the end. Research summary, not a recommendation.

What it is

Metformin is a small synthetic molecule of the biguanide class, not a peptide. It descends from guanidine compounds found in French lilac (goat's rue), a folk remedy for diabetes, and was introduced in Europe in the late 1950s and approved by the FDA in 1994. It is a first-line, FDA-approved prescription drug for type 2 diabetes and one of the most prescribed medicines in the world; interest in it for healthy ageing comes from observational and animal data and a planned aging trial, not from an approved use.

How it works

Metformin's main effect is to lower the amount of glucose the liver releases into the blood, especially overnight and between meals. It does this partly by mildly slowing complex I of the mitochondria (the cell's energy factories), which shifts the liver cell's energy balance and switches on AMPK, an enzyme that acts as a cellular fuel gauge and turns down glucose and fat production. More recent work also points to effects in the gut, where it raises the release of the hormone GLP-1, changes the gut bacteria and increases glucose use by the intestine. Unlike insulin or sulfonylureas it does not push the pancreas to release more insulin, so on its own it rarely causes low blood sugar.

What it has been studied for

  • Blood-sugar control and complications in type 2 diabetes (large randomized trials; FDA approved)
  • Preventing type 2 diabetes in people at high risk (large randomized trial)
  • Healthy ageing and age-related disease (reviews and a proposed aging trial)
  • Interaction with exercise training in older adults (randomized placebo-controlled trials)
  • Use in people with reduced kidney function (systematic review)

Strength of the evidence

Approved drugMetformin is FDA-approved for type 2 diabetes with decades of randomized-trial and outcome data; its use for ageing or longevity has no approval and rests on observational and animal evidence.

What the literature reports on safety

The FDA label lists stomach upset, diarrhoea and nausea as the most common side effects and carries a boxed warning for lactic acidosis, a rare but serious build-up of acid in the blood, mainly with significantly reduced kidney function, liver disease, heavy alcohol use, or around iodinated contrast imaging; a systematic review found that use with mild to moderate kidney impairment was reasonable with appropriate adjustment. Long-term use is associated with lower vitamin B12 levels. In randomized trials in older adults metformin blunted gains from exercise training, reducing the mitochondrial improvement from aerobic training and the muscle gain from resistance training.

Key papers

  1. Metformin: update on mechanisms of action and repurposing potential (opens in a new tab)

    Review · Foretz M, Guigas B, et al. · Nature Reviews Endocrinology (2023) · PMID 37130947

    Reviewed how metformin lowers liver glucose output, its effects on mitochondria, AMPK and the gut, and the evidence for repurposing it in cancer, ageing and other conditions.

  2. Cellular and Molecular Mechanisms of Metformin Action (opens in a new tab)

    Review · LaMoia TE, Shulman GI · Endocrine Reviews (2021) · PMID 32897388

    Weighed the competing explanations for how metformin works, including changes in the liver cell's redox state and energy balance and actions in the intestine.

  3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) (opens in a new tab)

    Randomized trial · UK Prospective Diabetes Study (UKPDS) Group · Lancet (1998) · PMID 9742977

    In overweight people with newly diagnosed type 2 diabetes, metformin reduced diabetes-related endpoints by 32% and all-cause death by 36% compared with conventional diet-based treatment.

  4. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (opens in a new tab)

    Randomized trial · Knowler WC, Barrett-Connor E, et al. · New England Journal of Medicine (2002) · PMID 11832527

    In the Diabetes Prevention Program, metformin cut new cases of diabetes by 31% versus placebo, while an intensive lifestyle program cut them by 58%.

  5. Metformin as a Tool to Target Aging (opens in a new tab)

    Review · Barzilai N, Crandall JP, et al. · Cell Metabolism (2016) · PMID 27304507

    Laid out the animal and observational evidence behind the proposed TAME trial, which aims to test whether metformin delays age-related diseases in people without diabetes.

  6. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults (opens in a new tab)

    Randomized trial · Konopka AR, Laurin JL, et al. · Aging Cell (2019) · PMID 30548390

    In older adults doing aerobic training, metformin cancelled the exercise-driven increase in muscle mitochondrial respiration seen with placebo.

  7. Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double-blind, placebo-controlled, multicenter trial: The MASTERS trial (opens in a new tab)

    Randomized trial · Walton RG, Dungan CM, et al. · Aging Cell (2019) · PMID 31557380

    Older adults on placebo gained more lean mass and thigh muscle from resistance training than those on metformin.

  8. Metformin in patients with type 2 diabetes and kidney disease: a systematic review (opens in a new tab)

    Review · Inzucchi SE, Lipska KJ, et al. · JAMA (2014) · PMID 25536258

    Found that lactic acidosis risk was low with mild to moderate kidney impairment and supported relaxing the older strict kidney cut-offs.

Sources checked: PubMed (E-utilities esummary and abstracts on every PMID), FDA label content as summarized in the cited reviews, written 2026-11-06.

Hunter Williams

→ profile

Protocol systematizer

Sources: compound titles first, then mentions

Taylor Williams

→ profile

Female-focused HRT + peptides

8 earlier videos were removed from YouTube; titles kept for the record

Dr Trevor Bachmeyer

→ profile

Acute vs chronic specialist

Sources: compound titles first, then mentions
7 earlier videos were removed from YouTube; titles kept for the record

Ask the Metformin Librarian

Answers are generated from captured sources and may omit context or contain errors. Check the supporting passages.

What have the teachers said about Metformin? Ask what it is, what they say it does, or where they discuss it. Questions about doses or personal use: ask your own clinician.

AI chat. To generate a reply, your question and recent chat history may be processed by Cloudflare Workers AI, Groq, Google Gemini or OpenRouter, depending on availability. Keep personal health details out of the chat and check the cited sources. Research use only; not medical advice.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

Metformin — Hunter, Taylor, Bachmeyer | Reset Biology